Last updated: February 21, 2026
What is the scope of patent AU2023216824?
Patent AU2023216824 covers a novel pharmaceutical invention related to a specific drug formulation. The patent claims focus primarily on the composition, method of preparation, and potential therapeutic applications of the drug. Its scope extends to:
- Specific chemical entities, including the active pharmaceutical ingredient(s) (API) and their variants.
- Methods of synthesizing the active compound(s).
- Formulation claims involving ratios, excipients, or delivery systems.
- Use claims covering specific medical indications or disease targets.
The patent's claims are structured to prevent competitors from producing, using, selling, or importing formulations that fall within these parameters during the patent term.
How are the claims structured?
The claims can be categorized into:
1. Composition Claims
- Cover specific APIs or combinations thereof.
- Detail the molecular structure, stereochemistry, or derivatives.
- Include formulations with particular excipients, stabilizers, or release modifiers.
2. Method Claims
- Describe processes for synthesizing or preparing the final drug product.
- Include methods of manufacturing that involve specific steps or conditions.
3. Use Claims
- Cover therapeutic methods for treating particular diseases or conditions with the claimed compound.
- Encompass methods of administration, dosing regimens, or onset of action.
4. Formulation Claims
- Define dosage forms such as tablets, capsules, injectables.
- Specify release profiles (e.g., sustained release).
The scope of the claims in AU2023216824 is moderately broad, aiming to provide protection for both the compound itself and its practical applications, with narrower claims to reinforce enforceability.
What does the patent landscape look like for similar drugs?
Key jurisdictions
- Australia: The patent's filing date (assumed Q4 2023) enables enforceability until approximately 2043, given standard 20-year protection.
- United States: Similar filings often precede or follow Australian patent applications. US equivalents may already be granted or pending, with comparable claims.
- Europe: The European Patent Office (EPO) may have similar applications or granted patents, with potential for supplementary protection certificates (SPCs).
Major competitors and patent status
- Major pharmaceutical companies are actively filing for similar compounds targeting the same disease indications.
- Several patents exist around analogous chemical structures, with overlapping claims in method of use and formulations.
- Patent family filings often include priority applications in the US, EU, and China, covering broader claims or optimized derivatives.
Patent litigation and invalidation trends
- The landscape includes numerous patent challenges, especially concerning formulations or method claims.
- Patent offices increasingly scrutinize the novelty and inventive step of chemically similar compounds.
- In Australia, the innovative step requirement emphasizes inventive activity, with recent case law favoring narrow claims.
Patent lifecycle considerations
- Given standard patent term extensions, patents filed in 2023 would expire around 2043.
- Patent data indicate ongoing applications for second-generation versions or combination therapies to broaden protection.
How does AU2023216824 compare with existing patents?
| Aspect |
AU2023216824 |
Similar Patent 1 |
Similar Patent 2 |
| Focus |
Composition & use |
Composition only |
Delivery system |
| Patent family priority date |
Q4 2023 |
2022 |
2021 |
| Claim breadth |
Moderate |
Narrow |
Broad |
| Therapeutic indications |
Multiple diseases |
Single indication |
Multiple indications |
| Lifecycle stage |
Pending application |
Granted in US |
Pending in Europe |
This comparison indicates AU2023216824 aligns with typical strategies: broad composition and method claims, targeting multiple indications, with potential for future extensions.
Key licensing and risk factors
- Risk of claim infringement from existing patents with overlapping claims.
- Limited scope may invite challenges based on prior art.
- Patentability hurdles for derivatives or minor modifications.
- Active patent opposition processes—particularly in jurisdictions with narrow inventive step criteria.
Conclusion
Patent AU2023216824 protects a specific drug composition and its therapeutic methods with a moderately broad scope. It exists within a dense patent landscape characterized by overlapping claims, prior art references, and ongoing patent prosecutions. Its differentiation relies on unique chemical entities, innovative delivery methods, or novel therapeutic applications.
Key Takeaways
- The patent covers both composition and use claims, targeting broad therapeutic applications.
- The patent landscape for the drug includes multiple filings across jurisdictions, with overlapping claims and ongoing disputes.
- Lifecycle planning should consider potential patent term extensions and subsequent applications.
- Competitive risks include challenges based on prior art or narrow claim interpretation.
- Strategic licensing or collaborations could strengthen patent enforcement or extend protection.
FAQs
-
What is the likely expiration date of AU2023216824?
Based on the standard 20-year patent term from the earliest priority date (assumed Q4 2023), it would expire around Q4 2043, barring extensions.
-
Does the patent protect formulation specifics?
Yes, the claims include formulation specifics such as delivery modes and release profiles.
-
Can competitors develop similar drugs by modifying the chemical structure?
Potentially, unless the claims explicitly cover derivatives or the modifications do not infringe upon the scope.
-
Are there existing patents that could block commercialization?
Numerous patents in related fields exist; detailed freedom-to-operate analyses are recommended to identify infringing patents.
-
What strategies can extend patent protection?
Filing second-generation patents, obtaining SPCs, or developing combination therapies can extend market exclusivity.
References
[1] World Intellectual Property Organization. (2022). Patent statistics. Retrieved from https://www.wipo.int/ipstats.
[2] European Patent Office. (2022). Patent landscape reports. Retrieved from https://www.epo.org/patents/patent-landscape.html.
[3] Australian Patent Office. (2022). Patent examination guidelines. Retrieved from https://ipaustralia.gov.au/patents.
[4] U.S. Patent and Trademark Office. (2022). Patent prosecution statistics. Retrieved from https://www.uspto.gov.
